Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study

• DOI: 10.1016/j.jaad.2023.02.040
• Publication Date: 2023-03-02T17:05:34Z
• Authors: Boni E. Elewski; Mark G. Lebwohl; Milan J. Anadkat; Jonathan Barker; Kamran Ghoreschi; Shinichi Imafuku; Ulrich Mrowietz; Ling Li; Manuel Quaresma; Christian Thoma; Hervé Bachelez
• Keywords: Generalized pustular psoriasis; Pustular psoriasis

Effisayil 1 was a randomized, placebo-controlled study of spesolimab, which is an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare.To assess the effects of spesolimab over the 12-week study.The primary endpoint of the study was Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 at week 1. Patients (N = 53) were randomized (2:1) to receive a single intravenous dose of 900 mg spesolimab or placebo on day 1. Patients could receive open-label spesolimab for persistent flare symptoms on day 8.Most patients receiving spesolimab achieved a GPPGA pustulation subscore of 0 (60.0%) and GPPGA total score of 0 or 1 (60.0%) by week 12. In patients randomized to placebo who received open-label spesolimab on day 8, the proportion with GPPGA pustulation subscore of 0 increased from 5.6% at day 8 to 83.3% at week 2. No factors predictive of spesolimab response were identified in patient demographics or clinical characteristics.The effect of initial randomization was not determined conventionally beyond week 1 due to patients receiving open-label spesolimab.Rapid control of generalized pustular psoriasis flare symptoms with spesolimab was sustained over 12 weeks, further supporting its potential use as a therapeutic option for patients.